| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
6,572 |
5,374 |
$533K |
| T1015 |
Clinic visit/encounter, all-inclusive |
11,427 |
2,045 |
$402K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
2,774 |
2,380 |
$316K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
3,429 |
3,277 |
$298K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,450 |
1,345 |
$59K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
283 |
263 |
$45K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
174 |
166 |
$31K |
| 80053 |
Comprehensive metabolic panel |
2,879 |
2,622 |
$28K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,224 |
2,849 |
$17K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
192 |
191 |
$15K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
170 |
169 |
$12K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
384 |
367 |
$11K |
| 70450 |
Computed tomography, head or brain; without contrast material |
172 |
167 |
$11K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
126 |
120 |
$10K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
639 |
383 |
$9K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
866 |
837 |
$9K |
| 80050 |
General health panel |
160 |
160 |
$9K |
| 84484 |
|
723 |
547 |
$8K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
762 |
695 |
$7K |
| 83880 |
|
223 |
206 |
$6K |
| 71046 |
Radiologic examination, chest; 2 views |
430 |
409 |
$6K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
39 |
39 |
$6K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
366 |
321 |
$5K |
| 80061 |
Lipid panel |
381 |
377 |
$5K |
| 84443 |
Thyroid stimulating hormone (TSH) |
375 |
360 |
$5K |
| 71045 |
Radiologic examination, chest; single view |
533 |
510 |
$4K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
156 |
155 |
$4K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
163 |
153 |
$3K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
170 |
169 |
$3K |
| 87040 |
|
164 |
132 |
$3K |
| 85730 |
|
461 |
438 |
$3K |
| 83735 |
|
496 |
444 |
$3K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
86 |
73 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
241 |
201 |
$3K |
| 85610 |
|
873 |
726 |
$2K |
| 83605 |
|
353 |
324 |
$2K |
| 73610 |
|
114 |
110 |
$2K |
| 83690 |
|
441 |
414 |
$2K |
| 73630 |
|
158 |
156 |
$2K |
| 84439 |
|
244 |
237 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
1,364 |
1,052 |
$2K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
13 |
13 |
$1K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
304 |
302 |
$1K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
325 |
311 |
$1K |
| 85378 |
|
125 |
123 |
$1K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
766 |
734 |
$1K |
| 81003 |
|
445 |
433 |
$1K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
184 |
171 |
$1K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
44 |
41 |
$1K |
| 73130 |
|
70 |
69 |
$937.84 |
| 81025 |
|
191 |
186 |
$844.59 |
| 81001 |
|
316 |
295 |
$788.73 |
| 76830 |
Ultrasound, transvaginal |
14 |
14 |
$737.06 |
| 76536 |
|
12 |
12 |
$626.15 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
20 |
19 |
$614.08 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
104 |
91 |
$604.76 |
| 85027 |
|
99 |
94 |
$603.59 |
| 82607 |
|
44 |
43 |
$595.68 |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
15 |
15 |
$531.52 |
| 82150 |
|
127 |
115 |
$530.72 |
| 87807 |
|
32 |
32 |
$498.62 |
| 85651 |
|
183 |
167 |
$486.25 |
| 84703 |
|
39 |
38 |
$389.43 |
| 82746 |
|
31 |
31 |
$382.17 |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
14 |
13 |
$308.26 |
| 72110 |
|
13 |
13 |
$298.22 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
32 |
32 |
$244.56 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,217 |
1,149 |
$233.71 |
| 73030 |
|
15 |
15 |
$215.94 |
| 87081 |
|
32 |
32 |
$201.83 |
| 87186 |
|
25 |
24 |
$190.10 |
| 73110 |
|
15 |
13 |
$153.18 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
759 |
701 |
$46.35 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
43 |
39 |
$39.74 |
| 82962 |
|
13 |
12 |
$21.75 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
56 |
54 |
$0.95 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
17 |
12 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
111 |
80 |
$0.00 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
16 |
12 |
$0.00 |